Drugs / camicinal
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01366560 | Aug → Oct 2010 | intestinal motility disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01267071 | Jun → Sep 2010 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01039974 | Sep → Nov 2009 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00733551 | Sep 2008 → Jul 2009 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00562848 | Sep 2007 → Jun 2008 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT02210000 | Aug 2014 → Aug 2015 | gastroparesis | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT01934192 | Apr 2014 → Jul 2016 | gastroparesis | GlaxoSmithKline | Terminated | Missed primary |
| Phase 2 | NCT01602549 | Jul 2012 → May 2014 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01262898 | May 2011 → Feb 2013 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01039805 | Dec 2009 → Jul 2011 | gastroparesis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00861809 | Jun 2009 → Nov 2010 | gastroparesis | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camicinal | “We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.” PMID 29278279 ↗ Dec 20173“the novel gastric promotility agent motilin agonist camicinal (GSK962040) in critically ill feed-intolerant patients” PMID 27476581 ↗ Aug 2016 “Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans.” PMID 28782145 ↗ Aug 2017 |
| Known as | GSK-962040B | ChEMBL registry synonym — accepted as the source's own label CHEMBL489095 ↗ |
| Known as | GSK962040 | “GSK962040 is a selective non-peptide motilin receptor agonist which is being developed for the treatment of conditions associated with slow rates of gastric emptying.” NCT01267071 ↗9“the novel gastric promotility agent motilin agonist camicinal (GSK962040) in critically ill feed-intolerant patients” PMID 27476581 ↗ Aug 2016 “GSK962040 is a selective non-peptide motilin receptor agonist” NCT01366560 ↗ |
| Action | Activate | “Camicinal (GSK962040), a small molecule motilin receptor agonist” PMID 28782145 ↗ Aug 20171“Motilin receptor agonist” CHEMBL489095 ↗ |
| Modality | Small molecule | “Camicinal (GSK962040), a small molecule motilin receptor agonist, has been shown to increase gastrointestinal motility.” PMID 28782145 ↗ Aug 2017 |
| Route | Oral | “the Oral Motilin Receptor Agonist GSK962040” NCT00562848 ↗ |
| Target | MLNR | “Motilin receptor agonist” CHEMBL489095 ↗ |